Skip to main content

Role of the SWI/SNF complex in the Androgen Receptor cistrome regulation

Project description

Unveiling the role of epigenetics in resistance to prostate cancer therapy

Testosterone and other androgen hormones exert their function by binding to the androgen receptor (AR) that acts as a transcription factor and activates the expression of specific target genes. In prostate cancer, inhibition of AR signalling constitutes the backbone of therapy, but resistance eventually develops. The EU-funded RegARcis project is investigating the mechanism underlying this resistance by focussing on chromatin-remodelling complexes. In particular, scientists will study the switch/sucrose non-fermentable (SWI/SNF) factors implicated in nucleosome rearrangement and chromatin accessibility. The idea is to determine potential redistribution of AR binding sites that may explain therapy resistance in advanced stages of the disease.

Call for proposal

H2020-MSCA-IF-2019
See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
Address
Avenida Gran Via Hospitalet 199-203
08908 L'hospitalet De Llobregat
Spain
Activity type
Research Organisations
EU contribution
€ 160 932,48